Browse by Audience
Skip to content
Papers of the Week
The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system.
Authors
Zhou Y, Wu Y, Zhao X, Xu L, Sun M, Meng ZAbstract
Ofatumumab is a humanized monoclonal antibody that targets CD20-positive B cells. It was approved by the FDA in 2020 for the treatment of relapsing multiple sclerosis (RMS) in adult patients, and in 2009 for the treatment of Chronic Lymphocytic Leukemia (CLL). With the escalating clinical application of Ofatumumab, comprehending its safety profile within actual healthcare environments is of considerable importance.